UNSPSC 51373438: Codeine/glycerol, iodinated

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373438 Codeine/glycerol, iodinated is a Commodity code under which state and local governments procure pharmaceutical products and related medical supplies for correctional, public health, and emergency-response applications. Recent solicitations show state and local buyers acquiring parenteral nutrition solutions, intravenous products, naloxone, and drug deactivation systems to support incarcerated populations, community health initiatives, and opioid-response programs. The work spans pharmaceutical supply, delivery logistics with strict time-to-order windows (ranging from 8 to 24 hours depending on product type), clinical monitoring capabilities, and compliance with controlled-substance handling and state pharmaceutical licensing requirements. State departments of corrections and county health departments are the primary issuing bodies under this code, with correctional health care representing the most active use case.

Recent opportunities surface in Washington and Florida. The Washington State Department of Corrections (DOC) issued RFQ RFQQK13020 on September 8, 2026, seeking parenteral products, services, and equipment for eight correctional facilities across the state, with bids due October 7, 2026, and a pre-bid conference on September 23, 2026; DOC encourages small business, minority-owned, women-owned, and veteran-owned enterprise participation and anticipates selecting up to three contractors per region with contract award beginning November 26, 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the bid response deadline was July 26, 2023. Both opportunities require detailed compliance with insurance, drug-free workplace, and E-Verify requirements, and both emphasize fixed pricing and strict delivery timelines as core performance conditions.